Developer docs
API playgroundTry for free, no card

Search company profiles

Alpha-1 Foundation

Full company profile

uuid000bona

Namestring
Alpha-1 Foundation
Legal namestring
Alpha-1 Foundation
Websiteurl
alpha1.org
Company typeenum
Private
Founded yearint
1991
Descriptiontext

The Alpha-1 Foundation is a 501(c)(3) nonprofit patient advocacy organization founded in 1991 and headquartered at 3300 Ponce de Leon Blvd., Coral Gables, Florida. Its mission is to find a cure for Alpha-1 Antitrypsin Deficiency, a genetic condition affecting an estimated 100,000 people in the United States (with 19 million carriers), over 90% of whom remain undiagnosed. The foundation serves three primary constituencies: Alpha-1 patients and carriers, healthcare providers, and researchers. Core programs include the Alpha-1 Research Registry (a confidential patient database supporting clinical trial enrollment), the Alpha-1 Coded Testing (ACT) Study (free home genetic testing in partnership with the University of Florida), genetic counseling, peer guides, a nationwide support group network, a Patient Information Line, the Alpha-1-to-One Magazine, and a video library of educational content. Educational programming includes an annual National Conference (held in San Diego in June 2026) and six regional Education Days across the U.S. The foundation also funds research grants (130 researchers supported to date), operates a Therapeutic Development Network and the Alpha-1 Biomarkers Consortium, and maintains a DNA and Tissue Bank and Biomaterials Exchange.

Short descriptiontext

The Alpha-1 Foundation is a 501(c)(3) nonprofit that funds research, provides free genetic testing, genetic counseling, and patient support services, and operates a research registry and AlphaDetect subsidiary to accelerate detection of Alpha-1 Antitrypsin Deficiency for patients, carriers, providers, and researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCoral Gables, United States
HQ citystring
Coral Gables
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
patient advocacy services, genetic testing programs, rare disease research funding, patient support services, disease awareness education
Industry2 codes
1Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
CodeBPAGACAAPrimaryYes
2Health & Medical Research Grantmaking Foundations
CodeBPAGAKALPrimaryNo
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Individual and Family Services6241
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Health Services8000
  • Services-Social Services8300
Product category
Patient Advocacy & Rare Disease Research Nonprofit
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

The Alpha-1 Foundation is a nonprofit patient advocacy organization that provides free programs and services to individuals affected by Alpha-1 Antitrypsin Deficiency, including confidential genetic testing (ACT Study), free genetic counseling, a Patient Information Line, a Peer Guide Program, a nationwide Support Group Network, and educational events. It funds and operates research infrastructure such as the Alpha-1 Research Registry, DNA and Tissue Bank, and Biomaterials Exchange, and has invested over $100 million in research across 130 funded researchers. Its wholly-owned nonprofit subsidiary, AlphaDetect (founded 2025, Durham, NC), accelerates detection through free genetic testing and provider education with support from pharmaceutical industry sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 90% of Alpha-1 affected individuals remain undiagnosed
+3 more records
Product overview1 text field

The Alpha-1 Foundation is a nonprofit organization offering a comprehensive suite of programs and services for individuals affected by Alpha-1 Antitrypsin Deficiency. The core offerings include the Alpha-1 Research Registry (a confidential patient database enabling clinical trial participation), the Alpha-1 Coded Testing (ACT) Study (free genetic testing), and AlphaDetect (a 2025-founded subsidiary focused on detection acceleration). Support services encompass the Peer Guide Program, Genetic Counseling Services, Patient Information Line, and a nationwide Support Group Network. Educational resources include the annual A1F National Conference, regional A1F Education Days, the A1F Video Library, and the Alpha-1-to-One Magazine. Financial assistance programs include Educational Scholarships and an Oxygen Travel Fund. The organization also maintains an Alpha-1 Specialist Network for patient referrals. This is not a commercial product company but a patient advocacy and support organization.

Product and service17 records
1Alpha-1 Research Registry
CategoryPatient Registry
Description

A confidential database of people with Alpha-1 Antitrypsin Deficiency and carriers that enables participation in clinical trials, recruitment by researchers, and distribution of research updates. Offered free of charge to U.S. residents affected by Alpha-1.

2Alpha-1 Coded Testing (ACT) Study
CategoryGenetic Testing Program
Description

Free, confidential genetic testing program providing a home fingerstick test kit to individuals, with results delivered in 4-6 weeks. Conducted in partnership with the University of Florida for individuals who may be affected by Alpha-1.

3AlphaDetect
CategoryDetection Program
Description

A nonprofit detection organization and wholly-owned subsidiary of the Alpha-1 Foundation, founded in 2025 and based in Durham, North Carolina, dedicated to accelerating detection of Alpha-1 Antitrypsin Deficiency through free genetic testing, provider education, and detection strategies.

4Peer Guide Program
CategoryPeer Support Service
Description

Connects newly diagnosed Alphas or individuals affected by Alpha-1 with experienced peer guides who provide emotional support and resources based on similar life circumstances.

5Genetic Counseling Services
CategoryGenetic Counseling
Description

Free, confidential genetic counseling services provided by phone through a partnership with the University of Florida, offering information about Alpha-1 testing, disease management, and family planning.

6Patient Information Line
CategoryPatient Helpline
Description

A free toll-free telephone helpline (1-800-245-6809) operated by the Director of Community Programs, providing patient support on Alpha-1 testing, emotional impact, finding specialists, peer guides, family planning, and care for children with Alpha-1.

7Alpha-1 Foundation Support Group Network
CategorySupport Group Network
Description

A nationwide program providing virtual and in-person support groups, education, and information to people affected by Alpha-1 across the United States.

8A1F National Conference
CategoryEducational Event
Description

The largest annual gathering of the Alpha-1 community, a three-day event offering educational sessions, networking, advocacy opportunities, and industry interaction for patients, families, providers, and researchers.

9A1F Education Days
CategoryEducational Event
Description

Regional one-day educational programs held across the U.S. in collaboration with Clinical Resource Centers or in underserved areas, providing medical information and community connection to people affected by Alpha-1.

10A1F Video Library
CategoryEducational Resource
Description

Archive of educational videos from past conferences and education days, organized by event year and topic including lung, liver, pediatric, genetics, and research content.

11Alpha-1-to-One Magazine
CategoryPublication
Description

Full-color magazine providing practical advice, personal experiences, and pertinent news for people affected by Alpha-1 Antitrypsin Deficiency, distributed to subscribers.

12Alpha-1 Educational Scholarships
CategoryFinancial Assistance
Description

Scholarship program supporting Alphas and their immediate family members pursuing post-high school education, including multiple named scholarships ranging from $500 to $2,500.

13Oxygen Travel Fund
CategoryFinancial Assistance
Description

Need-based program providing supplemental oxygen and related equipment for financially-eligible Alphas traveling to doctor appointments and educational events.

14Alpha-1 Specialist Network
CategorySpecialist Referral Service
Description

Searchable database of doctors specializing in Alpha-1, filterable by location and area of expertise (lung adult, lung pediatric, liver adult, liver pediatric), to help patients find appropriate care.

15Building Friends for a Cure (BFC)
CategoryFundraising Program
Description

Community fundraising program enabling individual supporters and teams to raise funds and awareness for Alpha-1 research and foundation programs.

16DNA and Tissue Bank
CategoryResearch Resource
Description

Research repository of DNA and tissue samples maintained by the Alpha-1 Foundation to support Alpha-1-related biomedical research.

17Biomaterials Exchange
CategoryResearch Resource
Description

Research resource providing Alpha-1 investigators with access to biomaterials to support laboratory and translational research.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-06-05
Description

Grifols became an inaugural industry sponsor of AlphaDetect, a nonprofit detection organization powered by the Alpha-1 Foundation. The sponsorship supports free genetic testing and expands provider education and detection strategies. This builds on Grifols' three-decade commitment to the Alpha-1 community and its existing testing program that has screened more than 1.5 million people.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Wave Life Sciences became an inaugural industry sponsor of AlphaDetect, a nonprofit subsidiary of the Alpha-1 Foundation. The sponsorship provides free genetic testing in Durham, NC laboratory and expands detection strategies and provider education efforts. This aligns with Wave Life Sciences' existing Alpha-1 pipeline program (WVE-006) and represents a strategic effort to connect patients to care and ongoing research.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Beam Therapeutics became an inaugural industry sponsor for AlphaDetect, a nonprofit subsidiary of the Alpha-1 Foundation. The sponsorship supports free genetic testing, healthcare providers, and scales detection efforts aligned with clinical guidelines. This builds on Beam Therapeutics' commitment to clinical research in the Alpha-1 community.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Sanofi became an inaugural industry sponsor of AlphaDetect, a nonprofit organization founded by the Alpha-1 Foundation. The sponsorship supports provider education, broadens detection strategies, and expands adoption of testing recommendations outlined in clinical practice guidelines.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-20
Description

The Weinbach Group established a client relationship with the Alpha-1 Foundation to improve its fundraising and outreach efforts. The agency develops and implements a communications program to expand awareness and support for A1F's initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AlphaNet is a website sponsor of the Alpha-1 Foundation and provides the Big Fat Reference Guide (BFRG) patient education resource. AlphaNet coordinators provide health management services to Alphas enrolled in augmentation therapy programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CSL (CSL Behring) is a website sponsor of the Alpha-1 Foundation. CSL manufactures augmentation therapy products and provides educational support for the Alpha-1 community.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Takeda is a website sponsor of the Alpha-1 Foundation and supports the foundation's educational programs and detection initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Alpha-1 Foundation partners with the University of Florida to provide free, confidential genetic counseling services by phone. The partnership also includes the Alpha-1 Coded Testing (ACT) Study which provides free home testing kits.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Rare disease policy and advocacy nonprofit focused on accelerating biotech innovation for rare diseases. Comparable as a rare-disease advocacy organization that engages with FDA, pharma sponsors, and patient communities to advance detection and treatment access.

TypeDirect peer
Description

The leading US nonprofit driving research, care, and detection of cystic fibrosis. Highly comparable as a disease-specific health nonprofit that funds a major research portfolio, operates a patient registry, and partners with pharmaceutical companies developing disease-modifying therapies.

TypeDirect peer
Description

Nonprofit advocacy organization for people with hemophilia and other bleeding disorders. Comparable as a rare-disease nonprofit that operates support programs, advocates for treatment access, and partners with plasma-derived and gene therapy developers.

TypeBroad incumbent
Description

Large disease-specific nonprofit combining research funding, patient services, and clinical care networks. Comparable operating model and sponsor mix, though MDA spans multiple neuromuscular conditions versus Alpha-1 Foundation's single-disease focus.

TypeDirect peer
Description

A wholly-owned venture philanthropy subsidiary of the Alpha-1 Foundation itself, focused on accelerating Alpha-1 therapeutic development. Direct peer and strategic affiliate operating within the same organization but with a distinct investment-oriented mission.

TypeDirect peer
Description

Nonprofit addressing liver disease, a major Alpha-1 manifestation. Comparable as a disease-area nonprofit that funds research, supports patients, and engages pharma, with overlapping clinical audience in Alpha-1 liver involvement.

TypeDirect peer
Description

Umbrella advocacy organization for rare diseases including Alpha-1. Comparable as a nonprofit that supports patient communities, drives research funding, and engages with the FDA and pharma on rare disease policy and detection initiatives.

TypeBroad incumbent
Description

Major nonprofit addressing lung disease broadly, including COPD and emphysema — common Alpha-1 manifestations. Comparable as a research-funding and patient-education organization that overlaps with Alpha-1's lung-disease focus but operates at much larger disease-category scope.

TypeDirect peer
Description

Nonprofit focused on primary immunodeficiency diseases, with comparable structure: patient registry, free testing/diagnostic programs, support groups, national conference, and pharmaceutical industry sponsorship to advance research and treatment access.

10Alpha-1 Alliance
TypeDirect peer
Description

Smaller nonprofit advocacy organization specifically focused on Alpha-1 Antitrypsin Deficiency policy and patient access. Direct peer serving the same patient population with overlapping policy and access-focused mission.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alpha-1 Foundation

Patient Advocacy & Rare Disease Research Nonprofitalpha1.org

The Alpha-1 Foundation is a 501(c)(3) nonprofit that funds research, provides free genetic testing, genetic counseling, and patient support services, and operates a research registry and AlphaDetect subsidiary to accelerate detection of Alpha-1 Antitrypsin Deficiency for patients, carriers, providers, and researchers.

What Alpha-1 Foundation does

The Alpha-1 Foundation is a 501(c)(3) nonprofit patient advocacy organization founded in 1991 and headquartered at 3300 Ponce de Leon Blvd., Coral Gables, Florida. Its mission is to find a cure for Alpha-1 Antitrypsin Deficiency, a genetic condition affecting an estimated 100,000 people in the United States (with 19 million carriers), over 90% of whom remain undiagnosed. The foundation serves three primary constituencies: Alpha-1 patients and carriers, healthcare providers, and researchers. Core programs include the Alpha-1 Research Registry (a confidential patient database supporting clinical trial enrollment), the Alpha-1 Coded Testing (ACT) Study (free home genetic testing in partnership with the University of Florida), genetic counseling, peer guides, a nationwide support group network, a Patient Information Line, the Alpha-1-to-One Magazine, and a video library of educational content. Educational programming includes an annual National Conference (held in San Diego in June 2026) and six regional Education Days across the U.S. The foundation also funds research grants (130 researchers supported to date), operates a Therapeutic Development Network and the Alpha-1 Biomarkers Consortium, and maintains a DNA and Tissue Bank and Biomaterials Exchange.

Alpha-1 Foundation firmographics

Firmographics
Name
Alpha-1 Foundation
Legal name
Alpha-1 Foundation
Website
https://alpha1.org
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
11–50 employees
Short description
The Alpha-1 Foundation is a 501(c)(3) nonprofit that funds research, provides free genetic testing, genetic counseling, and patient support services, and operates a research registry and AlphaDetect subsidiary to accelerate detection of Alpha-1 Antitrypsin Deficiency for patients, carriers, providers, and researchers.
Ownership category
akta.pro rank

Alpha-1 Foundation industry classification

Industry
Product category
Patient Advocacy & Rare Disease Research Nonprofit
NAICS
Voluntary Health Organizations (813212), Individual and Family Services (6241)
SIC
Services-Medical Laboratories (8071), Services-Health Services (8000), Services-Social Services (8300)
akta.pro primary industry
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
akta.pro secondary industry
Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

  • Patient advocacy services
  • Genetic testing programs
  • Rare disease research funding
  • Patient support services
  • Disease awareness education

Where Alpha-1 Foundation is headquartered

Location

Headquarters

HQ city
Coral Gables
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alpha-1 Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Distribution channels4 records

Marketing channels8 records

Alpha-1 Foundation product offering

Product offering

Core offering

The Alpha-1 Foundation is a nonprofit patient advocacy organization that provides free programs and services to individuals affected by Alpha-1 Antitrypsin Deficiency, including confidential genetic testing (ACT Study), free genetic counseling, a Patient Information Line, a Peer Guide Program, a nationwide Support Group Network, and educational events. It funds and operates research infrastructure such as the Alpha-1 Research Registry, DNA and Tissue Bank, and Biomaterials Exchange, and has invested over $100 million in research across 130 funded researchers. Its wholly-owned nonprofit subsidiary, AlphaDetect (founded 2025, Durham, NC), accelerates detection through free genetic testing and provider education with support from pharmaceutical industry sponsors.

Product overview

The Alpha-1 Foundation is a nonprofit organization offering a comprehensive suite of programs and services for individuals affected by Alpha-1 Antitrypsin Deficiency. The core offerings include the Alpha-1 Research Registry (a confidential patient database enabling clinical trial participation), the Alpha-1 Coded Testing (ACT) Study (free genetic testing), and AlphaDetect (a 2025-founded subsidiary focused on detection acceleration). Support services encompass the Peer Guide Program, Genetic Counseling Services, Patient Information Line, and a nationwide Support Group Network. Educational resources include the annual A1F National Conference, regional A1F Education Days, the A1F Video Library, and the Alpha-1-to-One Magazine. Financial assistance programs include Educational Scholarships and an Oxygen Travel Fund. The organization also maintains an Alpha-1 Specialist Network for patient referrals. This is not a commercial product company but a patient advocacy and support organization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alpha-1 Research Registry A confidential database of people with Alpha-1 Antitrypsin Deficiency and carriers that enables participation in clinical trials, recruitment by researchers, and distribution of research updates. Offered free of charge to U.S. residents affected by Alpha-1.
  • Alpha-1 Coded Testing (ACT) Study Free, confidential genetic testing program providing a home fingerstick test kit to individuals, with results delivered in 4-6 weeks. Conducted in partnership with the University of Florida for individuals who may be affected by Alpha-1.
  • AlphaDetect A nonprofit detection organization and wholly-owned subsidiary of the Alpha-1 Foundation, founded in 2025 and based in Durham, North Carolina, dedicated to accelerating detection of Alpha-1 Antitrypsin Deficiency through free genetic testing, provider education, and detection strategies.
  • Peer Guide Program Connects newly diagnosed Alphas or individuals affected by Alpha-1 with experienced peer guides who provide emotional support and resources based on similar life circumstances.
  • Genetic Counseling Services Free, confidential genetic counseling services provided by phone through a partnership with the University of Florida, offering information about Alpha-1 testing, disease management, and family planning.
  • Patient Information Line A free toll-free telephone helpline (1-800-245-6809) operated by the Director of Community Programs, providing patient support on Alpha-1 testing, emotional impact, finding specialists, peer guides, family planning, and care for children with Alpha-1.
  • Alpha-1 Foundation Support Group Network A nationwide program providing virtual and in-person support groups, education, and information to people affected by Alpha-1 across the United States.
  • A1F National Conference The largest annual gathering of the Alpha-1 community, a three-day event offering educational sessions, networking, advocacy opportunities, and industry interaction for patients, families, providers, and researchers.
  • A1F Education Days Regional one-day educational programs held across the U.S. in collaboration with Clinical Resource Centers or in underserved areas, providing medical information and community connection to people affected by Alpha-1.
  • A1F Video Library Archive of educational videos from past conferences and education days, organized by event year and topic including lung, liver, pediatric, genetics, and research content.
  • Alpha-1-to-One Magazine Full-color magazine providing practical advice, personal experiences, and pertinent news for people affected by Alpha-1 Antitrypsin Deficiency, distributed to subscribers.
  • Alpha-1 Educational Scholarships Scholarship program supporting Alphas and their immediate family members pursuing post-high school education, including multiple named scholarships ranging from $500 to $2,500.
  • Oxygen Travel Fund Need-based program providing supplemental oxygen and related equipment for financially-eligible Alphas traveling to doctor appointments and educational events.
  • Alpha-1 Specialist Network Searchable database of doctors specializing in Alpha-1, filterable by location and area of expertise (lung adult, lung pediatric, liver adult, liver pediatric), to help patients find appropriate care.
  • Building Friends for a Cure (BFC) Community fundraising program enabling individual supporters and teams to raise funds and awareness for Alpha-1 research and foundation programs.
  • DNA and Tissue Bank Research repository of DNA and tissue samples maintained by the Alpha-1 Foundation to support Alpha-1-related biomedical research.
  • Biomaterials Exchange Research resource providing Alpha-1 investigators with access to biomaterials to support laboratory and translational research.

Quantifiable outcome

  • Over 90% of Alpha-1 affected individuals remain undiagnosed
  • +3 more outcomes

Companies that use Alpha-1 Foundation

Customer profile

Segments3 records

Ideal customer profiles3 records

Alpha-1 Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Alpha-1 Foundation partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered major, minor and core.

  • GrifolsmajorStrategic or Co-development Partner · 5 June 2026Grifols became an inaugural industry sponsor of AlphaDetect, a nonprofit detection organization powered by the Alpha-1 Foundation. The sponsorship supports free genetic testing and expands provider education and detection strategies. This builds on Grifols' three-decade commitment to the Alpha-1 community and its existing testing program that has screened more than 1.5 million people.
  • Wave Life SciencesmajorStrategic or Co-development Partner · 19 May 2026Wave Life Sciences became an inaugural industry sponsor of AlphaDetect, a nonprofit subsidiary of the Alpha-1 Foundation. The sponsorship provides free genetic testing in Durham, NC laboratory and expands detection strategies and provider education efforts. This aligns with Wave Life Sciences' existing Alpha-1 pipeline program (WVE-006) and represents a strategic effort to connect patients to care and ongoing research.
  • Beam TherapeuticsmajorStrategic or Co-development Partner · 13 May 2026Beam Therapeutics became an inaugural industry sponsor for AlphaDetect, a nonprofit subsidiary of the Alpha-1 Foundation. The sponsorship supports free genetic testing, healthcare providers, and scales detection efforts aligned with clinical guidelines. This builds on Beam Therapeutics' commitment to clinical research in the Alpha-1 community.
  • SanofimajorStrategic or Co-development Partner · 6 May 2026Sanofi became an inaugural industry sponsor of AlphaDetect, a nonprofit organization founded by the Alpha-1 Foundation. The sponsorship supports provider education, broadens detection strategies, and expands adoption of testing recommendations outlined in clinical practice guidelines.
  • The Weinbach GroupminorImplementation/ SI/ Consulting Partner · 20 February 2026The Weinbach Group established a client relationship with the Alpha-1 Foundation to improve its fundraising and outreach efforts. The agency develops and implements a communications program to expand awareness and support for A1F's initiatives.
  • AlphaNetcoreStrategic or Co-development PartnerAlphaNet is a website sponsor of the Alpha-1 Foundation and provides the Big Fat Reference Guide (BFRG) patient education resource. AlphaNet coordinators provide health management services to Alphas enrolled in augmentation therapy programs.
  • CSLcoreStrategic or Co-development PartnerCSL (CSL Behring) is a website sponsor of the Alpha-1 Foundation. CSL manufactures augmentation therapy products and provides educational support for the Alpha-1 community.
  • TakedacoreStrategic or Co-development PartnerTakeda is a website sponsor of the Alpha-1 Foundation and supports the foundation's educational programs and detection initiatives.
  • University of FloridacoreStrategic or Co-development PartnerThe Alpha-1 Foundation partners with the University of Florida to provide free, confidential genetic counseling services by phone. The partnership also includes the Alpha-1 Coded Testing (ACT) Study which provides free home testing kits.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Alpha-1 Foundation competitors and assessment

Company assessment

Direct peers

  • EveryLife Foundation for Rare Diseases: Rare disease policy and advocacy nonprofit focused on accelerating biotech innovation for rare diseases. Comparable as a rare-disease advocacy organization that engages with FDA, pharma sponsors, and patient communities to advance detection and treatment access.
  • Cystic Fibrosis Foundation: The leading US nonprofit driving research, care, and detection of cystic fibrosis. Highly comparable as a disease-specific health nonprofit that funds a major research portfolio, operates a patient registry, and partners with pharmaceutical companies developing disease-modifying therapies.
  • Hemophilia Federation of America: Nonprofit advocacy organization for people with hemophilia and other bleeding disorders. Comparable as a rare-disease nonprofit that operates support programs, advocates for treatment access, and partners with plasma-derived and gene therapy developers.
  • The Alpha-1 Project (TAP): A wholly-owned venture philanthropy subsidiary of the Alpha-1 Foundation itself, focused on accelerating Alpha-1 therapeutic development. Direct peer and strategic affiliate operating within the same organization but with a distinct investment-oriented mission.
  • American Liver Foundation: Nonprofit addressing liver disease, a major Alpha-1 manifestation. Comparable as a disease-area nonprofit that funds research, supports patients, and engages pharma, with overlapping clinical audience in Alpha-1 liver involvement.
  • National Organization for Rare Disorders (NORD): Umbrella advocacy organization for rare diseases including Alpha-1. Comparable as a nonprofit that supports patient communities, drives research funding, and engages with the FDA and pharma on rare disease policy and detection initiatives.
  • Immune Deficiency Foundation: Nonprofit focused on primary immunodeficiency diseases, with comparable structure: patient registry, free testing/diagnostic programs, support groups, national conference, and pharmaceutical industry sponsorship to advance research and treatment access.
  • Alpha-1 Alliance: Smaller nonprofit advocacy organization specifically focused on Alpha-1 Antitrypsin Deficiency policy and patient access. Direct peer serving the same patient population with overlapping policy and access-focused mission.

Broad incumbents

  • Muscular Dystrophy Association: Large disease-specific nonprofit combining research funding, patient services, and clinical care networks. Comparable operating model and sponsor mix, though MDA spans multiple neuromuscular conditions versus Alpha-1 Foundation's single-disease focus.
  • American Lung Association: Major nonprofit addressing lung disease broadly, including COPD and emphysema — common Alpha-1 manifestations. Comparable as a research-funding and patient-education organization that overlaps with Alpha-1's lung-disease focus but operates at much larger disease-category scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Alpha-1 Foundation social profiles

Digital presence

Alpha-1 Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alpha-1 Foundation leadership team

Management profile

Number of profiles

Profiles5 records

Alpha-1 Foundation subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Alpha-1 Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alpha-1 Foundation M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alpha-1 Foundation

What does Alpha-1 Foundation do?

The Alpha-1 Foundation is a nonprofit patient advocacy organization that provides free programs and services to individuals affected by Alpha-1 Antitrypsin Deficiency, including confidential genetic testing (ACT Study), free genetic counseling, a Patient Information Line, a Peer Guide Program, a nationwide Support Group Network, and educational events. It funds and operates research infrastructure such as the Alpha-1 Research Registry, DNA and Tissue Bank, and Biomaterials Exchange, and has invested over $100 million in research across 130 funded researchers. Its wholly-owned nonprofit subsidiary, AlphaDetect (founded 2025, Durham, NC), accelerates detection through free genetic testing and provider education with support from pharmaceutical industry sponsors.

Is Alpha-1 Foundation a public or private company?

Alpha-1 Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Alpha-1 Foundation founded?

Alpha-1 Foundation was founded in 1991. It employs 11 to 50 people.

Where is Alpha-1 Foundation based?

Alpha-1 Foundation is headquartered in Coral Gables, United States, in the North America region.

Who are Alpha-1 Foundation's main competitors?

Direct peers on record are EveryLife Foundation for Rare Diseases, Cystic Fibrosis Foundation, Hemophilia Federation of America, The Alpha-1 Project (TAP), American Liver Foundation, National Organization for Rare Disorders (NORD), Immune Deficiency Foundation and Alpha-1 Alliance. Broad incumbents are Muscular Dystrophy Association and American Lung Association.

Does Alpha-1 Foundation have an API?

No public API is recorded for Alpha-1 Foundation.

What industry is Alpha-1 Foundation in?

Alpha-1 Foundation's product category is Patient Advocacy & Rare Disease Research Nonprofit. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireALPHA-1 FOUNDATION ENGAGES MIAMI COMMUNICATIONS FIRM TO ACCELERATE FUNDRAISINGThe Weinbach Group, a Miami-based healthcare marketing agency, announced a new client relationship with the Alpha-1 Foundation to help accelerate fundraising for the foundation's mission to find a cure for Alpha-1 Antitrypsin Deficiency, a rare genetic condition affecting the lungs and liver. The Alpha-1 Foundation has deployed over $100 million toward research over its 30-year history, leveraging those dollars by nearly a factor of 8 to result in more than $750 million in ancillary funding. The firm will initially determine feasibility for a capital campaign and execute a communications program to expand the foundation's reach to new audiences and fundraising sources.PR NewswireAlpha-1 Foundation Launches Innovative New Model for Centralized DetectionThe Alpha-1 Foundation announced the formation of AlphaDetect, a new non-profit subsidiary aimed at centralizing detection of Alpha-1 Antitrypsin Deficiency, a genetic condition that causes lung and liver disease and remains undiagnosed in over 90% of affected individuals. AlphaDetect will offer free genetic testing through a proprietary laboratory, provide physician support, and create an incubator space for detection-related research, with the initiative launching in mid-2026. The subsidiary will be funded by the Alpha-1 Foundation, industry partners including CSL as the first contributing partner, and community fundraising.PR NewswireAnnouncing Andrew A. Wilson MD as the Alpha-1 Foundation's new Scientific DirectorThe Alpha-1 Foundation has appointed Andrew A. Wilson, MD as its new Scientific Director. Dr. Wilson aims to advance research and treatment for Alpha-1 Antitrypsin Deficiency (Alpha-1), particularly focusing on chronic obstructive pulmonary disease (COPD). He has been involved with the Alpha-1 community since 2006 and emphasizes the importance of patient participation in research.PR NewswireThe Alpha-1 Foundation Announces New Chair of the Board of DirectorsThe Alpha-1 Foundation announced the selection of Jon Hagstrom as its new Chair of the Board of Directors, succeeding Dr. Jeanine D'Armiento after her four-year tenure that included the pandemic period. Hagstrom, who was diagnosed as a ZZ Alpha in 2008 and received a bilateral lung transplant at Duke University Medical Center in 2016, has been an active Foundation member since 2019 and will assume the role in July 2022. He brings over 20 years of investment banking and management consulting experience, along with extensive involvement in Alpha-1 research, patient support, and advocacy efforts.PR NewswireAlpha-1 Foundation Board Has New ChairThe Alpha-1 Foundation announced Jeanine D'Armiento, MD, PhD, as the new chair of its board of directors, effective July 31, 2018. D'Armiento, a Professor of Medicine in Anesthesiology at Columbia University, has been involved in Alpha-1 Antitrypsin Deficiency research since her early career and previously served on the Foundation's board since 2011. The announcement included additional executive committee changes, with James Quill named treasurer and Kenneth Irvine as the newest board member.PR NewswireNovember is Alpha-1 Awareness MonthThe Alpha-1 Foundation has designated November as Alpha-1 Awareness Month to increase public knowledge of Alpha-1 Antitrypsin Deficiency and promote research funding. The organization is encouraging affected individuals to participate in educational events, fundraisers, and a virtual walk while urging undiagnosed patients with COPD or liver disease to seek testing.